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Abstract
Purpose—The aim of this study was to describe the methods, cases, and initial results of a pilot 
project using existing public health data collection programs (birth defect surveillance or newborn 
screening) to conduct long-term follow-up of children with metabolic disorders.
Methods—California, Iowa, New York, and Utah expanded birth defect surveillance or newborn 
screening programs to collect long-term follow-up data on 19 metabolic disorders. Data elements 
to monitor health status and services delivered were identified, and record abstraction and data 
linkages were conducted. Children were followed up through to the age of 3 years.
Results—A total of 261 metabolic cases were diagnosed in 1,343,696 live births (19.4 cases/
100,000; 95% confidence interval = 17.1–21.8). Four deaths were identified. Children with fatty 
acid oxidation disorders had a higher percentage of health service encounters compared with 
children with other disorders of at least one health service encounter (hospitalization, emergency 
room, metabolic clinic, genetic service provider, or social worker) except for hospitalizations; 
children with organic acid disorders had a higher percentage of at least one hospitalization during 
their third year of life than children with other disorders.
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Conclusion—Existing public health data programs can be leveraged to conduct population-
based newborn screening long-term follow-up. This approach is flexible according to state needs 
and resources. These data will enable the states in assessing health burden, assuring access to 
services, and supporting policy development.
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Introduction
Newborn screening (NBS) long-term follow-up (LTFU) begins on confirmed diagnosis of a 
disorder1 and may continue throughout life. With the expansion of the recommended 
uniform screening panel in all the US states,2 it has become increasingly important to 
develop the means to understand the long-term health outcomes and resource use in 
newborns detected through public health NBS. Additionally, national activities such as the 
charter of the Secretary's Advisory Committee on Heritable Disorders in Newborns and 
Children (SACHDNC) in 2003 and passage of the Newborn Screening Saves Lives Act 
(NBSSLA 2008) have increased interest nationally to better understand the long-term 
outcomes. The SACHDNC has also issued policy statements on the importance of LTFU.3,4
The components of LTFU include care coordination through a medical home, evidence-
based practice, continuous quality improvement, and new knowledge discovery to maximize 
optimal outcomes for affected children.3 However, population-based, LTFU data for such 
children are challenging to capture due to the following reasons: (i) lack of programs in 
place to systematically capture and assess outcomes and (ii) lack of standards for data 
elements, sources, and case definitions.5,6 Nationally, efforts are beginning to explore the 
means to capture LTFU data. The Maternal and Child Health Bureau of the Health 
Resources and Services Administration funded a national network of regional genetics and 
NBS collaboratives7 that produced several projects aimed at strengthening LTFU.8–10 The 
National Institute of Child Health and Human Development funded the Newborn Screening 
Translation Research Network to develop data capacity among clinical centers to support 
outcomes research.11
Recently, the Centers for Disease Control and Prevention (CDC) funded a pilot project to 
enhance the collection and quality of population-based data for children with a confirmed 
metabolic NBS disorder via existing birth defect surveillance and NBS programs. The 
purpose of the project is to demonstrate the feasibility of expanding existing population-
based, public health data collection programs (birth defect surveillance or NBS) to conduct 
LTFU of children with 1 of the 19 metabolic disorders through to the age of 3 years. Such 
high-quality, collaborative data collection programs are needed to conduct surveillance, 
maintain assurance of care, identify areas for quality improvement, and better understand the 
epidemiology of recently added NBS disorders. Existing efforts to collaboratively collect 
and disseminate birth defect surveillance data have largely focused on structural 
malformations and chromosomal disorders.12 The addition of case finding and LTFU for 
confirmed NBS disorders would utilize existing standardized data elements (such as 
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demographic information) to provide centralized, uniform reporting of such disorders by 
demographic and clinical characteristics. This article presents an overview of the project 
methodology, case inclusion, and initial descriptive results.
Materials and Methods
Four states, California, Iowa, New York, and Utah, received a CDC grant to participate in 
this pilot project. Iowa and Utah expanded their state-wide, ongoing, active birth defect 
surveillance programs to include LTFU data on confirmed metabolic disorders; New York 
strengthened the existing linkages among administrative and clinical program databases 
(New York City births were not included)13; and California enhanced its statewide NBS 
reporting program to better collect LTFU data.14 To carry out LTFU, each state had legal 
authority to access the data needed, as well as established relationships and demonstration of 
cooperation with appropriate partners (e.g., birth defect surveillance and NBS programs, 
vital records, and appropriate health-care providers), to facilitate access to both short- and 
long-term outcome data.
Birth cohorts
Each state was required to monitor a minimum of 100,000 live births for a 3-year follow-up 
period. State and CDC investigators developed a data set with variables for demographics, 
health-care service encounters, and major clinical outcomes. Cases were live-born infants 
with a confirmed metabolic disorder identified by the respective state's NBS program. The 
birth cohorts for each state are summarized in Table 1. The goal was to follow up each child 
through to the third birthday, with data collection completed for each year of follow-up. 
Attrition could result from the following: (i) death, (ii) moving out of the catchment area, 
(iii) treatment deemed unnecessary by the provider, (iv) parental refusal of follow-up, or (v) 
lost to follow-up.
Case definition
This project relied on each state to use its defined case definition for the 19 selected 
metabolic disorders for case inclusion (Table 2). Case definitions for very-long-chain acyl-
CoA dehydrogenase deficiency (VLCADD) and 3-methylcrotonyl-CoA carboxylase 
deficiency were known to differ somewhat across states; project medical geneticists 
developed a surveillance case definition for each disorder (see Supplementary Table S1 
online) and reviewed all cases of very-long-chain acyl-CoA dehydrogenase deficiency and 
3-methylcrotonyl-CoA carboxylase deficiency in the cohort to standardize the final case 
inclusion.
Data collection
Standardized data elements were developed to capture information about health status and 
use of services. Specific data domains included diagnosis, treatments (e.g., medical diet and 
medications), encounters with specific service providers (e.g., medical geneticist, metabolic 
dietitian, genetic counselor, and social worker), growth, development, hospitalizations, 
comorbidities, and mortalities. A data dictionary, modeled based on the National Birth 
Defects Prevention Network data set,15 was created (see Supplementary Table S2 online). 
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Resources used to develop the data elements included the American College of Medical 
Genetics and Genomics' ACTion Sheets, the Regional Genetics and NBS 
Collaboratives,8,10,16,17 and the existing data dictionaries used by the participating states' 
surveillance and NBS programs.
Key staff, including principal investigators and data managers, from the four participating 
sites and CDC met via biweekly conference calls over the first year to develop the data 
elements. A data source hierarchy was established for each element in consultation with 
medical record abstractors. A mid-year data collection trial was undertaken to assess the 
process and the feasibility of merging data from each state. Data elements were refined 
accordingly, and by the end of the first year, the data dictionary had 121 elements, plus 
additional text fields for further annotation of the data. Of these elements, 40 (33%) 
overlapped with the National Birth Defects Prevention Network recommended data elements 
for birth defect surveillance and included demographics, diagnostic tests, and mortality.
Follow-up data were collected using different strategies. Metabolic clinics in California are 
contractually obligated to submit annual data to the Genetic Disease Screening Program in 
the California Department of Public Health. Iowa, New York, and Utah had trained 
abstractors to collect clinical and administrative data. Each state submitted anonymized, 
individual-level data for each year of follow-up. Data were transferred to CDC via a secured 
file transfer protocol. Subsequent data transmission occurred semiannually, and the data 
elements continued to be refined over the course of the project. All data analyses were 
conducted using SAS 9.3 (SAS Institute, Cary, NC).
Results
The state NBS programs identified 261 infants with one of the 19 eligible metabolic 
disorders among 1,343,696 live births (Table 2) for an overall prevalence of 19.4/100,000 
live births (95% confidence interval = 17.1–21.8). Descriptive epidemiology of the infants 
and mothers are provided in Table 3. Approximately 60% of the infants were non-Hispanic 
white and 26% were Hispanic. A majority of mothers had health insurance, with 52% 
covered by private insurance and 38% covered by Medicaid or other public insurance. Cases 
were primarily located in metropolitan counties, with 49% located in a metro county of 1 
million or greater population. A majority of the mothers (62%) were between 23 and 34 
years of age. Three disorders accounted for 69% of all cases: medium-chain acyl-CoA 
dehydrogenase deficiency (6.0/100,000 live births), phenylketonuria (PKU; 4.3/100,000 live 
births), and 3-methylcrotonyl-CoA carboxylase deficiency (3.1/100,000 live births) (Table 
2).
Health-care service encounters over the 3-year follow-up period are summarized in Table 4. 
Changes in denominators reflect children who died or moved out of the catchment area the 
previous year. During the first year, 38% of children had at least one hospitalization and 
27% had at least one emergency room visit. At the year 3 of follow-up, a drop was observed 
in both hospitalization (12%) and emergency room visits (14%). Overall, 88% received care 
at a metabolic clinic at least once during their first year of life, 77% had at least one 
metabolic clinic visit during their second year, and 74% during their third year. During the 
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first year of follow-up, 94% of children saw a metabolic geneticist at least once, 78% saw a 
metabolic dietitian, 51% saw a genetic counselor, and 36% saw a social worker. Compared 
with year 1, the percentage of encounters with each type of provider decreased during year 2 
and further decreased during year 3.
Compared with children with amino acid or organic acid disorders, a higher percentage of 
children with fatty acid oxidation disorders had at least one encounter with each type of 
health service (Table 4) during the 3-year follow-up except for one health service: 
hospitalization. More children with organic acid disorders had at least one hospitalization 
during their third year of life compared with children with the other two groups of disorders. 
Hospitalizations for year 3 and dietitian visits for years 1 and 2 were differed significantly (P 
< 0.05)
There were four deaths identified before the age of 3 years (1 in 65 or 1.7% overall). Of 
these, two had VLCADD, one had methylmalonic aciduria, and one had glutaric acidemia 
type 1. The condition-specific mortality by the age of 3 years was 10.5% for VLCADD (2 
deaths/19 affected), 25% for methylmalonic aciduria (1 death/4 affected), and 9% for 
glutaric acidemia type 1 (1 death/11 affected). Two deaths associated with VLCADD 
occurred at 4 days and 10 weeks of age, the death associated with methylmalonic aciduria 
occurred at 16 days of age, and the death associated with glutaric acidemia type 1 occurred 
at 21 months of age. The births of these four children were covered under public insurance. 
Among the four mothers of each deceased infant or child, three had less than high school 
education or high school graduation or general education degree. Each mother was a resident 
of a large urban area. There were no mortalities attributed to amino acid disorders.
Discussion
With the expansion of disorders in the Secretary of Health and Human Services' 
Recommended Uniform Screening Panel,18 health-care providers and public health 
programs are increasingly confronted with difficult questions on how best to monitor, follow 
up, and evaluate the success of NBS. From a public health perspective, critical gaps in 
knowledge remain, including the population-wide impact of NBS conditions, comorbidities, 
and mortality and the associated use of services, disparities, and outcomes. Studies 
originating from metabolic clinics are helpful, particularly in establishing clinical guidelines, 
but limited in their ability to follow up an entire population, including those families who 
drop out of the clinical follow-up.
A population-based question requires a population-based solution and ideally one that is 
standard based, sustainable, and practical, focusing on key public health questions. State 
public health programs could benefit from considering the feasible methods to conduct and 
evaluate LTFU for affected children, especially by leveraging existing birth defects 
surveillance or NBS programs to conduct LTFU of affected children using standardized data 
elements. This pilot project not only improved the state-level data but also provided pooled 
data that permitted a better understanding of rare disorders that might otherwise require 
many years for a single state to gather enough cases to better understand the long-term 
outcomes of these children.
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The guiding principle behind the data elements used was to capture enough information but 
not to become a burdensome activity for state programs to assess both access to specialty-
care follow-up services and health outcomes of children with metabolic disorders detected 
through mandated NBS. Overall, the data elements will help public health programs to 
conduct core public health functions of assessment (prevalence, mortality, and morbidities), 
assurance (access to services and bridging gaps), and support policy development best 
practices (programmatic and clinical). Data on specific clinical visits, treatments, or 
laboratory values were not as detailed as those that might be captured through other NBS 
LTFU projects8,11 or through focused clinical investigations. The data set is flexible and can 
be tailored to accommodate state needs and resources. At a minimum, a LTFU data set 
would include the diagnosis, providers (specialty or general pediatrician), and annual 
indicators of vital and follow-up status. A state might use the opportunity to verify treatment 
in a medical home, which could also be of benefit for children detected through NBS who 
might not be followed up in a specialty clinic.
Prevalence estimates for the most common disorders reported in this pilot project were 
comparable to other published US data. The estimate for 3-methylcrotonyl-CoA carboxylase 
deficiency (3.1/100,000 live births) was comparable with 2006 data from a four-state study 
of expanded NBS (2.4)19 and from the National Newborn Screening Information System 
national database (2.3).20 Likewise, the estimates for medium-chain acyl-CoA 
dehydrogenase deficiency (6.0/100,000 live births) and for PKU (4.3/100,000 live births) 
were compared, respectively, with those for medium-chain acyl-CoA dehydrogenase 
deficiency (5.819 and 5.320) and PKU (5.219 (which included cases of clinically significant 
hyperphenylalaninemia) and 4.220) from each of these previously mentioned data sources. 
Rates of common metabolic disorders (e.g., PKU) vary by race and ethnicity; therefore, 
some variation among states can be expected, given differences in population composition.21 
Furthermore, at the time of the data collection, there were no standard US-based surveillance 
case definitions; thus, case definitions might vary across states and regions.
Data for service encounters during the first 3 years of life showed that almost all children 
identified (94%) were seen by a metabolic geneticist at least once during their first year of 
life. This first-year visit is expected because most of these children would need to be seen 
for a diagnosis and treatment plan. By the third year, the number of children who saw a 
metabolic geneticist dropped to 82%. The second most commonly seen specialist was a 
metabolic nutritionist (78% in the first year and 64% in the third year). Such visits will vary 
based on the diagnosis (e.g., a child with PKU should have a service encounter with a 
dietitian, whereas a child with medium-chain acyl-CoA dehydrogenase deficiency might 
not). It is worth noting that there is no indication that 6% of the infants saw a metabolic 
geneticist at least once during their first year, an observation that would need to be 
confirmed through further study. There are no best practice guidelines by which to evaluate 
the types and frequency of service encounters over the 3-year pilot period. Moreover, for 
families of newborns identified through the respective state's dried blood spot screening, 
there are limited published reports about the numbers of encounters with genetic service 
providers.22
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This public health surveillance approach has several strengths. First, existing public health 
programs were leveraged to identify and track children with metabolic disorders for 3 years. 
This permitted project activities to be included under public health surveillance laws or 
administrative rule, use established infrastructures and data elements, and minimize start-up 
costs. Second, our design was population based rather than clinical center based. Cases were 
identified through each state's NBS program rather than through a particular clinical-center 
catchment area, which permitted follow-up of a defined birth cohort to minimize selection 
bias. Third, each state used a multiple-source ascertainment that included vital records, NBS 
reports, and, in some instances, administrative databases, such as hospital discharge data. 
This multiple-source methodology can increase a program's sensitivity to monitor the long-
term outcomes of children detected through NBS. The methodology also provides an 
opportunity to initiate or strengthen connections with other specialty providers, primary-care 
providers, and medical homes.
This project has several limitations. First, it was challenging to capture service encounters 
for other service providers beyond the genetic specialists, e.g., other medical geneticists (not 
metabolic), nursing encounters, and physical or occupational therapists. Possible reasons for 
this included data source limitations, need for such services in the first 3 years of life, or 
need for improved definitions of data elements. For example, the “nurse” term was generic 
so that it was challenging to capture such information uniformly. Second, the availability of 
certain outcome data was limited by the type of data sources. Although administrative 
databases yielded information on hospitalizations, emergency room visits, morbidities, and 
mortalities, they did not include information on other variables, such as service encounters 
for other providers, treatments, and developmental outcomes. These data could only be 
obtained from a genetics clinic. During the course of the project, New York investigators 
added medical record abstraction to their methods in order to capture data from the genetics 
clinic data. Administrative data sources made it difficult to ascertain if hospitalizations or 
emergency room visits were due to the metabolic disorder or due to other factors. Because 
the service encounter outcomes data were obtained mostly from metabolic clinics, 
encounters or outcomes collected by primary-care providers or other providers would be 
missed in this model, without developing alternative sources and the ability to link data 
sets.6 For instance, the family of a child with a mild metabolic disorder might decide to 
discontinue follow-up through the metabolic clinic and be managed by a primary-care 
provider. Due to the severity of many metabolic disorders, however, one would expect 
children to be managed by specialists at metabolic clinics.
Ideally, the need for LTFU spans from birth to adulthood, encompassing preconception and 
prenatal care for women. The length of time designated for LTFU is often determined by the 
rules and regulations of the state and by available resources. Long-term clinical studies are 
beyond the scope of typical public health surveillance, but the need to assure developmental 
outcomes and successful life transitions (entering school, adolescence, learning self-care, 
and transition to post-high school) remains a public health concern. the ability to link 
surveillance data with other public health systems could be tremendously useful to assure 
that children are receiving recommended well care (immunizations), appropriate early 
services (early intervention systems), and Medicaid claims (treatments and documenting 
health service utilization) and that they are assessing school progress (education). 
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Incorporating informatics, such as HL7 and electronic health records, into existing birth 
defects surveillance can only help in improving states' abilities to conduct long-term follow-
up of children detected through public health NBS. Leveraging existing resources becomes 
even more critical to LTFU success.
In summary, this project demonstrated the feasibility of expanding and enhancing state 
public health data collection programs to include LTFU for children detected by NBS. 
Public health surveillance in the 21st century will need to rely on multiple data sources to 
guide program planning, interventions, and family support.23,24 It will also need to consider 
resource restraints and adapt to the changing landscape of NBS. For these reasons, an 
approach that leverages existing public health data collection programs may help decrease 
time to program implementation and operation costs. This public health surveillance 
approach is one of several regional and national efforts to contribute toward NBS LTFU data 
projects.8–10,16,17,25 These projects collectively encourage collaboration among public 
health and clinical stakeholders to ensure optimal health and outcomes for persons with 
metabolic disorders.
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Table 1
State birth cohorts
State Cohort years Live births
California 2006a–2007 808,429
Iowa 2005–2007 120,815




2006 data are for August to December.
b
Excluding New York City.
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Table 2
Population-based prevalence of the 19 metabolic disorders from four states (California, 
Iowa, New York, and Utah)
Type Disorder Cases Percentage of cases Rate/100,000 live births (95% CI)
Organic acid 3MCC 42 16.1 3.1 (2.2–4.1)
MUT 15 5.7 1.1 (0.6–1.7)
GA1 11 4.2 0.8 (0.3–1.3)
IVA 4 1.5 0.3 (0.0–0.6)
MMA, cblA and cblB forms 4 1.5 0.3 (0.0–0.6)
PROP 2 0.8 0.2 (0.0–0.4)
Fatty acid MCADD 80 30.7 6.0 (4.7–7.3)
VLCADD 19 7.3 1.4 (0.8–2.0)
CUD 12 4.6 0.9 (0.4–1.4)
LCHADD 1 0.4 0.1 (0.0–0.2)
Amino acid PKU 58 22.2 4.3 (3.2–5.4)
MSUD 7 2.1 0.5 (0.1–0.9)
ASA 4 1.5 0.3 (0.0–0.6)
CIT 2 0.8 0.2 (0.0–0.4)
Totala 261 100.0 19.4 (17.1–21.8)
3MCC, 3-methylcrotonyl-CoA carboxylase deficiency; ASA, argininosuccinic acudiuria; BKT, β-ketothiolase deficiency; CUD, carnitine uptake 
defect; CI, confidence interval; CIT, citrullinemia; GA1, glutaric acidemia type 1; HCY, homocystinuria; HMG, hydroxymethylglutaryl lyase 
deficiency; IVA, isovaleric acidemia; LCHADD, long-chain hydroxyacyl-CoA dehydrogenase deficiency; MSUD, maple syrup urine disease; 
MCADD, medium-chain acyl-CoA dehydrogenase deficiency; MCD, multiple-CoA carboxylase deficiency; MMA, methylmalonic aciduria; MUT, 
methylmalonyl-CoA mutase deficiency; PKU, phenylketonuria; PROP, propionic acidemia; TFP, trifunctional protein deficiency; VLCADD, very-
long-chain acyl-CoA dehydrogenase deficiency.
a
There were no cases of HMG, BKT, MCD, TFP, or HCY.
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Table 3
Case contribution by state and case demographic information
Characteristic N Percentage
Confirmed metabolic cases by state
 California 132 51
 Iowa 21 8
 New York (excluding New York city) 57 22
 Utah 51 19
Infant sex
 Male 147 56
 Female 114 44
Maternal race/ethnicity
 White/non-Hispanic 155 59
 Black/non-Hispanic 10 4
 Hispanic 69 26
 Asian/Pacific Islander 22 8
 Other/unknown 5 2
Insurance
 Private 136 52
 Medicaid/public 98 38
 Self-pay 7 3
 Other 6 2
 Unknown 14 5
Rural–urban continuum
 Large urban (metro area ≥1 million population) 129 49
 Small urban (metro area <1 million population) 112 43
 Large rural (nonmetro area with urban population ≥20,000) 9 3
 Small rural (non-metro area with urban population <20,000) 11 4
Mother's education
 <HS 58 22
 HS/GED 60 23
 Some college/associate's degree 60 23
 College/postcollege degree 77 30
 Unknown 6 2
Maternal age (years)
 ≤23 59 23
 24–34 162 62
 ≥35 40 15
Gravidity
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Characteristic N Percentage
 1 96 37
 2 73 28
 ≥3 89 34
 Unknown 3 1
GED, general education degree; HS, high school.
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